Physician profile
James E Questel
NPI 1689057259
$3,151.63
in general payments reported to CMS, 2019-2025
17 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.00 · 2020: $7.76 · 2021: $40.70 · 2022: $17.31 · 2023: $1,092 · 2024: $951 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,076.09 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Viiv Healthcare Company | $1,047.41 | 2023-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $155.52 | 2023-2025 | |
| Napo Pharmaceuticals INC | $125.50 | 2023-2024 | Mytesi |
| Antares Pharma, INC. | $99.61 | 2024-2025 | Xyosted |
| Janssen Biotech, INC. | $95.73 | 2020-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $75.58 | 2023-2024 | Pifeltro, Delstrigo, Dificid |
| Lilly USA, LLC | $75.26 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Theratechnologies INC. | $72.18 | 2023-2024 | Trogarzo, Egrifta, Egrifta Sv |
| Emd Serono, INC. | $62.05 | 2025 | |
| Novo Nordisk INC | $48.24 | 2024-2025 | Wegovy, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.45 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.80 | 2024-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $40.67 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $38.69 | 2024-2025 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $30.85 | 2024 | Tlando |
| Exact Sciences Corporation | $25.00 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Questel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.